Proactive Investors - Run By Investors For Investors

GW Pharmaceuticals RNS Release

Posting of Shareholder Circular

RNS Number : 2213N
GW Pharmaceuticals PLC
21 October 2016

GW Pharmaceuticals plc

Posting of Shareholder Circular

London, UK, 21 October 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, confirms that further to the announcement made on 19 October, a circular has been published and has been posted to shareholders in relation to the Company's intention to cancel the admission of its 0.1 pence ordinary shares to trading on AIM on 5 December, 2016.

A copy of the Circular is available on the Company's website at the following URL:



GW Pharmaceuticals plc

Stephen Schultz, VP Investor Relations (U.S.)

917 280 2424 / 401 500 6570

FTI Consulting (Media Enquiries)

Ben Atwell / Simon Conway

+44 20 3727 1000

Peel Hunt LLP (UK NOMAD)

James Steel

+44 20 7418 8900


This information is provided by RNS
The company news service from the London Stock Exchange

GW Pharmaceuticals Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use